Actively Recruiting
Evaluating AZD2389 Safety and Effects in Adults With Steatotic Liver Disease and Advanced Fibrosis Using a Placebo-Controlled Randomized Study
Led by AstraZeneca · Updated on 2026-11-03
104
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacodynamic effects of AZD2389 in adults with steatotic liver disease SLD and advanced fibrosis. This phase IIa study aims to better understand how this oral drug works in treating chronic liver diseases with advanced fibrosis, including cirrhosis. The research involves about 230 screened participants, with 104 adults expected to be randomly assigned to treatment groups. Participants will be divided into two groups one receiving AZD2389 orally for up to 24 weeks and the other receiving a placebo. The study lasts approximately 32 weeks, including 4 weeks of screening, 24 weeks of treatment, and a 4-week follow-up. Visits occur about every 4 weeks except between visits 2 and 4, which happen every 2 weeks. The study is double-blind and randomized to compare the effects of AZD2389 versus placebo. During the trial, participants will have regular assessments including blood pressure, heart rate, oxygen levels, body temperature, respiratory rate, and laboratory tests of blood and urine samples. The main outcome measured is the change in Enhanced Liver Fibrosis ELF score after 24 weeks. Additional tests include liver stiffness and collagen markers. Safety will be monitored throughout treatment and follow-up. Participants involvement will last up to 32 weeks, with multiple visits to track health and liver function.
CONDITIONS
Brief Title
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here